PressAugust 24, 2021 MindMed Announces Collaboration With Forian To Advance Development Of Personalized Psychiatry For Anxiety Disorders
PressAugust 24, 2021 Mindset Pharma Broadens its IP Portfolio by Filing U.S. Provisional Patent Extending its DMT and 5-MeO-DMT Inspired Psychedelic Drug Candidates
PressAugust 20, 2021 Silo Wellness Announces $3 Million U.S. Sales and Distribution Partnership for Marley One Line of Functional Mushrooms
PressAugust 19, 2021 Cybin Files Two Additional International Patent Applications in Support of the Company’s Research Phase Programs
PressAugust 17, 2021 Mydecine Innovations finishes 2Q with C$7M in cash after busy research period pinpoints four new lead drug candidates
PressAugust 17, 2021 Beckley Psytech completes oversubscribed $80m fundraise to develop portfolio of psychedelic medicine breakthroughs
PressAugust 16, 2021 atai Life Sciences Reports Second Quarter 2021 Financial Results and Business Update
PressAugust 13, 2021 Core One Labs’ Clinics Submit Application to Treat Patient With Psilocybin Psychedelic-Assisted Therapy
PressAugust 12, 2021 Awakn Life Sciences Begins Trading on the OTCQB(R) Venture Market Under the Symbol ‘AWKNF’ on August 12th
PressAugust 9, 2021 Ketamine One to Provide Scent-Enabled Virtual Reality Via Exclusive Agreement for Psychedelic Molecules With OVR Technology
PressAugust 6, 2021 COMPASS Pathways plc to announce second quarter 2021 financial results on 11 August 2021
PressAugust 5, 2021 PharmaDrug Forms Research Collaboration with Terasaki Institute for Novel Ocular Drug Formulation Program to Deliver DMT and Other Tryptamines to Treat Eye Disease
PressAugust 4, 2021 Awakn Life Sciences Announces Its Second Location in the UK for “Awakn Clinics London,” Providing Treatment to the Largest City in the UK
PressAugust 3, 2021 MindMed Joins Digital Medicine Society to Improve Health Outcomes and Equity Using Technology
